Cargando…

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma(1–3). The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Platten, Michael, Bunse, Lukas, Wick, Antje, Bunse, Theresa, Le Cornet, Lucian, Harting, Inga, Sahm, Felix, Sanghvi, Khwab, Tan, Chin Leng, Poschke, Isabel, Green, Edward, Justesen, Sune, Behrens, Geoffrey A., Breckwoldt, Michael O., Freitag, Angelika, Rother, Lisa-Marie, Schmitt, Anita, Schnell, Oliver, Hense, Jörg, Misch, Martin, Krex, Dietmar, Stevanovic, Stefan, Tabatabai, Ghazaleh, Steinbach, Joachim P., Bendszus, Martin, von Deimling, Andreas, Schmitt, Michael, Wick, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046668/ https://www.ncbi.nlm.nih.gov/pubmed/33762734 http://dx.doi.org/10.1038/s41586-021-03363-z

Ejemplares similares

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
por: Grassl, Niklas, et al.
Publicado: (2023)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
por: Bunse, Lukas, et al.
Publicado: (2022)

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
por: Blobner, Jens, et al.
Publicado: (2021)

T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
por: Lu, Kevin Hai-Ning, et al.
Publicado: (2022)

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
por: Kilian, Michael, et al.
Publicado: (2022)

Genetically Modified Cellular Therapies for Malignant Gliomas
por: Kilian, Michael, et al.
Publicado: (2021)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
por: Hunger, Jessica, et al.
Publicado: (2023)

Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
por: Seidel, Clemens, et al.
Publicado: (2011)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
por: Friedrich, Mirco, et al.
Publicado: (2022)

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease
por: Breckwoldt, Michael O., et al.
Publicado: (2019)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
por: Kickingereder, Philipp, et al.
Publicado: (2015)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
por: Kessler, Tobias, et al.
Publicado: (2020)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

Gd contrast administration is dispensable in patients with MS without new T2 lesions on follow-up MRI
por: Karimian-Jazi, Kianush, et al.
Publicado: (2018)

Clinical and Translational Advances in Glioma Immunotherapy
por: Bunse, Lukas, et al.
Publicado: (2022)

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
por: Ott, Martina, et al.
Publicado: (2012)

Large-scale characterization of the microvascular geometry in development and disease by tissue clearing and quantitative ultramicroscopy
por: Hahn, Artur, et al.
Publicado: (2020)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

Diagnostic value of gadolinium contrast administration for spinal cord magnetic resonance imaging in multiple sclerosis patients and correlative markers of lesion enhancement
por: Karimian-Jazi, Kianush, et al.
Publicado: (2021)

Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
por: Elmadany, Nirmeen, et al.
Publicado: (2022)

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
por: Bunse, Lukas, et al.
Publicado: (2022)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Clinical Value of Susceptibility Weighted Imaging of Brain Metastases
por: Schwarz, Daniel, et al.
Publicado: (2020)

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
por: Kaulen, Leon D, et al.
Publicado: (2022)

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
por: Turco, Verena, et al.
Publicado: (2023)

Monitoring innate immune cell dynamics in the glioma microenvironment by magnetic resonance imaging and multiphoton microscopy (MR-MPM)
por: Karimian-Jazi, Kianush, et al.
Publicado: (2020)

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
por: Wick, A., et al.
Publicado: (2022)

Correlated magnetic resonance imaging and ultramicroscopy (MR-UM) is a tool kit to assess the dynamics of glioma angiogenesis
por: Breckwoldt, Michael O, et al.
Publicado: (2016)

Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors
por: Platten, Michael, et al.
Publicado: (2015)

Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ
por: Kudo, Takumi, et al.
Publicado: (2020)

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
por: Litzenburger, Ulrike M., et al.
Publicado: (2014)

Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
por: Caramanna, Ivan, et al.
Publicado: (2022)

Chemotherapy for intracranial ependymoma in adults
por: Gramatzki, Dorothee, et al.
Publicado: (2016)

Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
por: Deistung, Andreas, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2hmpj46eab6cnojsorhovksdth